223 related articles for article (PubMed ID: 6285799)
21. Evaluation of commercial EBV RecombLine assay for diagnosis of nasopharyngeal carcinoma.
Paramita DK; Fachiroh J; Haryana SM; Middeldorp JM
J Clin Virol; 2008 Aug; 42(4):343-52. PubMed ID: 18455473
[TBL] [Abstract][Full Text] [Related]
22. Native early antigen of Epstein-Barr virus, a promising antigen for diagnosis of nasopharyngeal carcinoma.
Paramita DK; Fachiroh J; Artama WT; van Benthem E; Haryana SM; Middeldorp JM
J Med Virol; 2007 Nov; 79(11):1710-21. PubMed ID: 17854043
[TBL] [Abstract][Full Text] [Related]
23. Serum anti-EBV IgA is inversely related to tumor infiltration by surface IgA positive lymphocytes in nasopharyngeal carcinoma.
Gunvén P; Klein G; Henle W; Henle G; Forsby N
Biomed Pharmacother; 1983; 37(1):41-4. PubMed ID: 6311307
[TBL] [Abstract][Full Text] [Related]
24. Immune responses to Epstein-Barr virus lytic proteins in patients with nasopharyngeal carcinoma.
Liu MY; Huang YT; Sheen TS; Chen JY; Tsai CH
J Med Virol; 2004 Aug; 73(4):574-82. PubMed ID: 15221902
[TBL] [Abstract][Full Text] [Related]
25. Epstein-Barr virus-associated antibodies and serum biochemistry in nasopharyngeal carcinoma.
Lynn TC; Hsieh RP; Chuang CY; Huang SC; Hsieh T; Tu SM
Laryngoscope; 1984 Nov; 94(11 Pt 1):1485-8. PubMed ID: 6092804
[TBL] [Abstract][Full Text] [Related]
26. [EBV-specific antibodies in patients with nasopharyngeal cancer and tonsillar cancer. Follow-up of over 4 years].
Oberender H; Nowak R; Donner A; Brichacek E; Vonka V; Teterin W; Kunkel M
Laryngorhinootologie; 1989 Mar; 68(3):181-5. PubMed ID: 2540762
[TBL] [Abstract][Full Text] [Related]
27. [Significance of cell-free Epstein-Barr virus DNA in monitoring prognosis of nasopharyngeal carcinoma].
Cao SM; Min HQ; Gao JS; Hong MH; Xiao XB; Zhang CQ; Liu XD; Zhang AL; Guo X
Ai Zheng; 2003 Mar; 22(3):302-6. PubMed ID: 12654192
[TBL] [Abstract][Full Text] [Related]
28. Comparison of three different serological techniques for primary diagnosis and monitoring of nasopharyngeal carcinoma in two age groups from Tunisia.
Karray H; Ayadi W; Fki L; Hammami A; Daoud J; Drira MM; Frikha M; Jlidi R; Middeldorp JM
J Med Virol; 2005 Apr; 75(4):593-602. PubMed ID: 15714486
[TBL] [Abstract][Full Text] [Related]
29. Serum responses to the combination of Epstein-Barr virus antigens from both latent and acute phases in nasopharyngeal carcinoma: complementary test of EBNA-1 with EA-D.
Chow KC; Ma J; Lin LS; Chi KH; Yen SH; Liu SM; Liu WT; Chen WK; Chang TH; Chen KY
Cancer Epidemiol Biomarkers Prev; 1997 May; 6(5):363-8. PubMed ID: 9149897
[TBL] [Abstract][Full Text] [Related]
30. [Atypical involvement of undifferentiated carcinomas of the nasopharyngeal type. Apropos of 3 cases].
Le Roy A; Honigman I; Chevalier E; Hazan A; Bodiguel V; Adotti F; Peytral C
Ann Otolaryngol Chir Cervicofac; 1998 Nov; 115(5):288-92. PubMed ID: 9881177
[TBL] [Abstract][Full Text] [Related]
31. Circulating immune complexes in patients with nasopharyngeal carcinoma.
Wolf GT; Wolfe RA
Laryngoscope; 1990 Mar; 100(3):302-8. PubMed ID: 1689798
[TBL] [Abstract][Full Text] [Related]
32. Histological types of nasopharyngeal carcinoma in an intermediate risk area.
Cammoun M; Ellouz R; Behi J; Attia RB
IARC Sci Publ (1971); 1978; (20):13-26. PubMed ID: 215511
[TBL] [Abstract][Full Text] [Related]
33. Histopathological types of nasopharyngeal carcinoma in a low-risk area: Japan.
Sugano H; Sakamoto G; Sawaki S; Hirayama T
IARC Sci Publ (1971); 1978; (20):27-39. PubMed ID: 215515
[TBL] [Abstract][Full Text] [Related]
34. Malaria antibody levels in patients with nasopharyngeal carcinoma.
Yadav M; Prasad U
Southeast Asian J Trop Med Public Health; 1984 Jun; 15(2):234-7. PubMed ID: 6095462
[TBL] [Abstract][Full Text] [Related]
35. Epstein-Barr virus DNA in nasopharyngeal carcinoma in Thai patients at Ramathibodi Hospital, Bangkok.
Niemhom S; Maeda S; Raksakait K; Petchclai B
Southeast Asian J Trop Med Public Health; 1995; 26 Suppl 1():325-8. PubMed ID: 8629135
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic value of Epstein-Barr viral serology in nasopharyngeal carcinoma.
Low WK; Leong JL; Goh YH; Fong KW
Otolaryngol Head Neck Surg; 2000 Oct; 123(4):505-7. PubMed ID: 11020195
[TBL] [Abstract][Full Text] [Related]
37. The association between undifferentiated nasopharyngeal carcinoma and Epstein-Barr virus shown by correlated nucleic acid hybridization and histopathological studies.
Andersson-Anvret M; Klein G; Forsby N; Henle W
IARC Sci Publ (1971); 1978; (20):347-57. PubMed ID: 83285
[TBL] [Abstract][Full Text] [Related]
38. Nasopharyngeal carcinoma in Japan--clinical evaluation of EBV serology and EBV-associated nuclear antigens test.
Takimoto T; Furukawa M; Morishita K; Umeda R; Hatano M
Auris Nasus Larynx; 1982; 9(3):151-63. PubMed ID: 6301414
[TBL] [Abstract][Full Text] [Related]
39. IgA/VCA as a follow-up marker in the monitoring of nasopharyngeal carcinoma.
Sam CK; Abu-Samah AJ; Prasad U
Eur J Surg Oncol; 1994 Oct; 20(5):561-4. PubMed ID: 7926060
[TBL] [Abstract][Full Text] [Related]
40. Epstein-Barr virus serology in the control of nasopharyngeal carcinoma.
Levine PH; Connelly RR; Milman G; Easton J
Cancer Detect Prev; 1988; 12(1-6):357-62. PubMed ID: 2846170
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
